|
Cell Centre Robust cell line development is seen by many as intensive and time-consuming, but it is key to process optimisation, particularly for recombinant therapeutic antibodies – ensuring stable production and lowering product costs Louis Boon, Bioceros BV (December 2013)
Keywords: Recombinant proteins,
Chinese hamster ovary
(CHO) cell lines,
Metabolic selection,
Biosimilar monoclonal
antibodies (mAbs),
Cost of goods (CoGs)
|